Pancreatic adenocarcinoma

This trial tests a new cell therapy called TC-510 for people with advanced cancers that have a protein called mesothelin on their surface, including mesothelioma, ovarian cancer, and pancreatic cancer. TC-510 uses a patient's own immune cells, which are genetically modified to be…

This phase 2 trial tests whether combining two drugs—erlotinib and everolimus—can slow the growth of advanced pancreatic cancer in patients who have already received at least one prior treatment. The study enrolls people with unresectable or metastatic pancreatic adenocarcinoma a…

This early-stage trial tested an experimental drug called PF-08052666 in 19 people with advanced solid tumors like lung, ovarian, and pancreatic cancers that had not responded to standard treatments. The drug is designed to target and kill cancer cells. The study aimed to find a …

This early-phase trial is testing whether adding two immunotherapy drugs (botensilimab and balstilimab) to a strong chemotherapy mix plus two oral medications (chloroquine and celecoxib) can help people with metastatic pancreatic cancer that hasn't been treated yet. The study inv…

This study looked at whether adding a precise type of radiation (stereotactic body radiation therapy) to standard chemotherapy could better control pancreatic cancer that has spread to only a few spots in the body. The trial planned to enroll patients with limited metastases, but…

This study tested a precision medicine approach for people with advanced cancers like breast, ovarian, pancreatic, prostate, or sarcoma. Researchers used genetic and protein tests to track how the cancer changes and then a team of experts recommended personalized drugs. The goal …

This very early trial tested two immune-stimulating drugs injected directly into tumors for people with stage IV pancreatic cancer. The goal was to see if the combination could shrink tumors or slow their growth. However, the study was stopped early after enrolling only 2 partici…

This study tested whether combining two drugs, trametinib and hydroxychloroquine, could help overcome treatment resistance in people with advanced pancreatic cancer that had spread. The trial aimed to see how many patients were free of cancer growth after 12 weeks. It included 20…

This study tested whether injecting chemotherapy drugs directly into pancreatic cysts could shrink or eliminate them. It involved 75 adults with cysts between 2-5 cm. The approach used an endoscope to guide the injection, comparing two different pre-treatment rinses. The trial wa…

This study aimed to see if injecting radioactive particles (OncoSil) directly into pancreatic tumors during an endoscopic ultrasound, combined with chemotherapy, could safely shrink tumors and improve survival. It was designed for people with advanced pancreatic cancer that could…

This early-phase study tested a treatment called huCART-meso cells, which are a patient's own immune cells modified to recognize and attack pancreatic cancer cells. The trial included 54 people with advanced pancreatic cancer that could not be removed by surgery. The main goal wa…

This early-phase trial tested an experimental drug called TAK-500, alone or with the immunotherapy pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The stud…

This early-stage trial tested a new drug called RP-3467, alone or with olaparib, in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated, so full results are no…

This study tested an experimental drug called APG-1387 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in people with advanced pancreatic cancer. The goal was to find the safest dose and see if the combination could shrink tumors. However, the trial was termi…

This early-phase trial tested whether adding the experimental drug YL-13027 to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe for people with advanced pancreatic cancer that no longer responds to treatment. Only 4 participants were enrolled before the study was st…

This early-phase study tested whether adding the experimental drug NIS793 to standard chemotherapy (FOLFIRINOX) could help people with metastatic pancreatic cancer. Only 4 people took part before the study was stopped. The goal was to find a safe dose and see if the combination c…

This trial tested a new drug called SOT102, alone or with standard chemotherapy, in 31 people with advanced pancreatic cancer. The goal was to find the safest dose and see if it helped shrink tumors. The study was stopped early because of unexpected safety problems that reappeare…

This early-phase trial tested a drug called CPI-613 (devimistat) combined with chemotherapy and radiation for people with pancreatic cancer that cannot be surgically removed. The goal was to find the safest dose. Only 8 people took part before the study was stopped. While the app…

This early-phase trial tested a new drug called ASP2074 in 23 adults with advanced solid tumors that had spread or couldn't be removed by surgery. The goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.

This phase 2 trial tested a drug called tusamitamab ravtansine, alone or with chemotherapy (gemcitabine), in 50 people with advanced breast or pancreatic cancers that have a specific marker (CEACAM5). The goal was to see if the drug could shrink tumors. The study was terminated e…

This phase 2 trial tested two drugs—ulixertinib and hydroxychloroquine—in 47 people with advanced gastrointestinal cancers that have certain genetic mutations (MAPK pathway). The goal was to see if the combination could shrink tumors. However, the study was terminated early, so t…

This study looked at whether a blood test that detects circulating tumor cells (CTCs) could diagnose pancreatic cancer. Researchers planned to compare the blood test results with standard tissue biopsies in 101 people with pancreatic tumors. The trial was terminated early, so the…

This study tested a drug called anamorelin to see if it could help prevent weight loss and improve appetite in people with advanced pancreatic cancer who were starting chemotherapy. The trial planned to include about 100 participants but was stopped early after only 4 people enro…

This pilot study aimed to find genetic differences, called microRNAs, that might explain why some pancreatic cancer patients lose muscle mass (cachexia). Researchers planned to analyze tumor samples from 40 patients undergoing surgery, focusing on African Americans who may be at …

This study aimed to see if a simple blood test (liquid biopsy) could help doctors make better treatment decisions for people with advanced cancers of the colon, pancreas, or bile duct. Researchers planned to enroll about 130 participants but stopped early with only 16 enrolled. T…